生物技术与制药领域的最新动态
Thermo Fisher Scientific: Assessing Value After Diagnostics Acquisition and Recent Share Price Gains - simplywall.st
Friday Five — Oral SERDs eye earlier opportunities, Agios' SCD miss, Avadel's not-so-sleepy bidding war…and more - FirstWord Pharma
Under RFK Jr., vaccine use slides while suspicion rises
Swiss Lonza Group plans to sell part of assets for 2.5 billion euros - AKM.RU
Roche inks deal for rights to Freenome cancer tests outside US - MedTech Dive
Regeneron wins 2 Eylea nods, ramping up competition with Roche - Fierce Pharma
Headless bodies hint at why Europe’s first farmers vanished
Saturna Capital Corp Has $63.66 Million Position in Agilent Technologies, Inc. $A - MarketBeat
Thermo Fisher Scientific’s Oncomine Dx Target Test Receives FDA Approval as a Companion Diagnostic to Identify Patients Eligible for Newest Targeted Therapy for Non-Small Cell Lung Cancer - Business Wire
Sierra Legacy Group Raises Stake in Agilent Technologies, Inc. $A - MarketBeat
Will 10x Genomics' (TXG) Role in ASTRA Shift Its Competitive Edge in Precision Oncology? - simplywall.st
Why Lonza Group AG (Common Stock) (LO3A) stock could be top winner - 2025 Major Catalysts & Smart Money Movement Alerts - newser.com
UBS Sticks to Its Buy Rating for Roche Holding AG (RHHVF) - The Globe and Mail
Spatial Biology Market Analysis and Forecast, 2025-2035: Stellaromics, RareCyte, and 10x Genomics Drive Innovation and Funding Momentum - Yahoo Finance
Moderna secures $1.5B lifeline as it looks to break even in 2028
Lonza Group AG Falls Friday, Underperforms Market - 富途牛牛
A megadam test for China and South Asia | Science
A bacterial toxin disarms gut defenses against inflammation | Science
The retina’s rhythm | Science
Engineering chromosome number in plants | Science